Analyst picks & changes

Synergen Inc.

Barbara Hoffman of Piper Jaffray initiated coverage of

Synergen Inc.

with a "buy," saying that SYGN is "misunderstood by an investor community that

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE